)
)
Combigene Investor Relations Material
Latest events
Investor Update
Combigene
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Combigene
Access all reports
CombiGene AB is a biotechnology company based in Sweden, focusing on developing gene therapies for severe neurological and psychiatric disorders. The company's primary projects include treatments for drug-resistant focal epilepsy and severe chronic pain. CombiGene utilizes gene therapy vectors, specifically adeno-associated virus (AAV) vectors, to deliver therapeutic genes. The company operates in collaboration with external research entities and contract research organizations to develop its therapeutic candidates from preclinical stages to proof of concept, aiming for subsequent commercialization through strategic partnerships. The company is headquartered in Lidingö, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
COMBI
Country
🇸🇪 Sweden